author-photo

Kerstin Luedtke-Heckenkamp

Harvard University

10

Papers

257

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Intraepithelial Lymphocytes in the Small Cell-Derived Chemoattractant for Fractalkine Is an Epithelial and Endothelial

2013
Show All
- Source
- Cite
- Save
Citations (0)
The mouse IL-17 receptor promoter is under autocrine control and regulated by two inhibitor/enhancer elements in intestinal epithelial cells

2000 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (0)
Fractalkine Is an Epithelial and Endothelial Cell-Derived Chemoattractant for Intraepithelial Lymphocytes in the Small Intestinal Mucosa

2000 Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (233)
Fractalkine is an epithelial and endothelial cell derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa

2000 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (1)